Postdoctoral Position Endocytosis, Signalling and Cancer Lab

IEO - European Institute of Oncology; Lombardia; On-site; EUR 36,000 - 41,000; Full time

Benefits offered by this job

Job summary

IEO - European Institute of Oncology in Milan, Italy invites applications for a Postdoctoral Position in the Endocytosis, Signalling and Cancer Lab. The project focuses on using PetSign and StemPrintER signatures to improve prognostic stratification in breast cancer and identify FDA-approved drugs targeting these phenotypes.

Responsibilities include deriving PetSign and StemPrintER risk scores, benchmarking them against existing predictors, and validating related genes in BC cell lines;

Qualifications

• PhD in Cancer Biology, Cell Biology, Molecular Biology, Systems Medicine or related life sciences.
• Strong experience in mammalian cell culture and functional assays.
• Experience in RNAseq, scRNAseq and bioinformatics.
• A genuine interest in translational cancer research.

Responsibilities

• Derivation of a PetSign risk score (PRS) and a StemPrintER risk score (SPRS).
• Benchmarking PRS and SPRS vs. available BC predictors.
• Molecular and phenotypic validation in BC lines of PetSign and StemPrintER genes.

Skills

Mammalian cell culture

Functional assays

RNAseq

scRNAseq

Bioinformatics

Translational cancer research

Education

PhD in Cancer Biology, Cell Biology, Molecular Biology, Systems Medicine or related life sciences

Job description

Postdoctoral Position Endocytosis, Signalling and Cancer Lab

IEO - European Institute of Oncology

Milan, Italy

€ 36.000 per year gross

About the Project:

Breast cancer management is hindered by extensive molecular and phenotypic heterogeneity. Despite advances in molecular stratification and precision medicine, major unmet clinical needs persist, particularly in intermediate-risk Luminal breast cancer and triple-negative breast cancer (TNBC), the most aggressive subtype.

Our laboratory has recently developed two multigene signatures: PetSign, capturing metabolic (glycolytic) alterations, and StemPrintER, reflecting the acquisition of cancer stem cell properties.

This project aims to leverage these signatures to improve prognostic stratification of Luminal and TNBC patients and to identify FDA-approved drugs capable of targeting these phenotypes.

Role and Responsibilities:

• Derivation of a PetSign risk score (PRS) and a StemPrintER risk score (SPRS);
• Benchmarking of PRS and SPRS vs. available BC predictors;
• Molecular and phenotypic validation in BC lines of genes of PetSign and StemPrintER.

Qualifications:

• A PhD in Cancer Biology, Cell Biology, Molecular Biology, Systems Medicine or a related life sciences discipline;
• Strong experience in mammalian cell culture and functional assays;
• Experience in RNAseq, scRNAseq, and bioinformatics;
• Familiarity with phenotypic heterogeneity and functional characterization of cancer cell states;
• A genuine interest in translational cancer research.

Deadline 21 November

IEO - European Institute of Oncology